Coagulation Assays

Shannon M. Bates, MD, MSc, FRCP(C); Jeffrey I. Weitz, MD, FRCP(C)

Case 1: Mr F, a 75-year-old man with diabetes, was admitted with non–ST-segment-elevation acute coronary syndrome. In addition to other medications, he is receiving 1 mg/kg enoxaparin every 12 hours. He is scheduled for cardiac catheterization later in the afternoon. Earlier this morning, his activated partial thromboplastin time (aPTT) was 30 seconds. How should his anticoagulants be managed?

Case 2: Mrs G was admitted with chest pain and shortness of breath. A ventilation-perfusion lung scan was consistent with a large pulmonary embolism. Because of renal dysfunction, initial therapy consisted of unfractionated heparin. After 2 days of intravenous heparin and 5 mg/d warfarin, her aPTT is 48 seconds, and her international normalized ratio (INR) is 1.3. She is currently receiving 45 000 U heparin per day. How should her anticoagulants be managed?

Normal Coagulation

Coagulation in arteries or veins is triggered by tissue factor, a cellular receptor for activated factor VII (VIIa) that is exposed after vessel wall injury.[1] Lipid-laden macrophages in the core of atherosclerotic plaques are particularly rich in tissue factor,[1] which explains the propensity for arterial thrombosis at sites of plaque disruption. Although direct injury also can induce thrombosis in veins, more commonly, coagulation is triggered by tissue factor–bearing monocytes or microparticles that become tethered to activated endothelial cells or platelets.

Once bound to tissue factor to form extrinsic tenase, factor VIIa activates factors IX and X (Figure 1). Factor Xa converts small amounts of prothrombin to thrombin.[2] This low concentration of thrombin amplifies coagulation by activating platelets[3] and factors V and VIII, key cofactors for coagulation.[4,5]

Coagulation is propagated when factor IXa binds to factor VIIIa on the surface of activated platelets or monocytes to form intrinsic tenase, a complex that efficiently activates factor X. Factor Xa then binds to factor Va to form prothrombinase, thereby increasing the rate of factor Xa–mediated conversion of prothrombin to thrombin >300 000-fold. The resultant burst of thrombin rapidly converts fibrinogen to fibrin, and fibrin monomers polymerize to form the fibrin mesh that is stabilized and cross-linked by factor XIIIa, a thrombin-activated transglutaminase.[2,6]

Aside from factor VIII, all coagulation factors are synthesized in the liver. The hepatic synthesis of factors VII, IX, X, and prothrombin is vitamin K dependent. Vitamin K is required for a posttranslational modification of these factors that results in gamma-carboxylation of glutamic acid residues at their N termini.[6] Gamma carboxylation endows these factors with the capacity to bind calcium and to interact with negatively charged phospholipid membranes. Without this step, vitamin K–dependent clotting factors are nonfunctional.

Abnormalities of Coagulation

In addition to hereditary deficiencies of coagulation factors, there are numerous acquired coagulation abnormalities. Hepatic dysfunction or vitamin K deficiency (resulting from inadequate dietary intake, malabsorption, or warfarin therapy) results in reduced production of functional coagulation factors. The coagulation disorder encountered in severe liver disease is compounded by enhanced fibrinolysis with resultant consumption of clotting factors. Vitamin K antagonists like warfarin block the gamma-carboxylation step, leading to synthesis of biologically inactive coagulation factors. Excess activation of coagulation can cause disseminated intravascular coagulation, which leads to con-

From the Departments of Medicine (S.M.B., J.I.W.) and Biochemistry and Medical Sciences (J.I.W.), McMaster University, and Henderson Research Centre (S.M.B., J.I.W.), Hamilton, Ontario, Canada.

Correspondence to Dr Jeffrey I. Weitz, Professor of Medicine and Biochemistry, McMaster University, Director, Henderson Research Centre, Henderson Research Centre, 711 Concession St, Hamilton, Ontario L8V 1C3, Canada. E-mail jweitz@thrombosis.hhscr.org

(*Circulation.* 2005;112:e53-e60.)

***Circulation* is available at http://www.circulationaha.org** **DOI: 10.1161/CIRCULATIONAHA.104.478222**



Figure 1. Coagulation pathways. Coagulation is initiated by extrinsic tenase, which forms when factor VIIa binds to tissue factor. Extrinsic tenase activates factors IX and X. In the presence of calcium, factor IXa binds to negatively charged phospholipid surfaces where it interacts with factor VIIIa to form intrinsic tenase, a complex that efficiently activates factor X. Factor Xa binds to factor Va on negatively charged phospholipid surfaces to form prothrombinase, the complex that activates prothrombin to thrombin. Thrombin then converts fibrinogen to fibrin. Activated platelets or monocytes provide negatively charged phospholipid surfaces on which these clotting reactions occur.

sumption of coagulation factors. Secondary fibrinolysis triggers breakdown of fibrin and generation of fibrin degradation products, which can impair hemostasis by inhibiting fibrin polymerization. Finally, factor deficiencies can be caused by autoantibodies against coagulation factors. These most often occur in hemophiliacs or in patients with autoimmune disorders.

Coagulation Assays

Several techniques, including clot-based tests, chromogenic or color assays, direct chemical measurements, and ELISAs, are used for coagulation testing.[7] Of these techniques, clot-based and chromogenic assays are used most often. Whereas clotting assays provide a global assessment of coagulation function, chromogenic tests are designed to measure the level or function of specific factors.

Clot-Based Assays

Clot-based assays are often used for evaluation of patients with suspected bleeding abnormalities and to monitor anticoagulant therapy (Table 1).[8] Most of these tests use citrated plasma, and the end point for all of them is fibrin clot formation. Some of the technical and analytic variables that can influence assay results are listed in Table 2.

Prothrombin Time

This test is performed by adding a thromboplastin reagent that contains tissue factor (which can be recombinant in origin or derived from an extract of brain, lung, or placenta) and calcium to plasma and measuring the clotting time (Figure 2A). The prothrombin time (PT) varies with reagent and coagulometer but typically ranges between 10 and 14 seconds.[9] The PT is prolonged with deficiencies of factors VII, X, and V, prothrombin, or fibrinogen and by antibodies directed against these factors. This test also is abnormal in patients with inhibitors of the fibrinogen-to-fibrin conversion reaction, including high doses of heparin and the presence of fibrin degradation products. Typically, PT reagents contain excess phospholipid so that nonspecific inhibitors (ie, lupus anticoagulants), which react with anionic phospholipids, do not prolong the clotting time.[10] The PT is most frequently used to monitor warfarin therapy.

Commercially available thromboplastins vary in their tissue factor source and method of preparation, leading to differing sensitivities to factor deficiencies[11]; therefore, PT results reported using different reagents are not interchangeable.[12] The INR corrects for differences in thromboplastin potency. The World Health Organization has established a reference thromboplastin against which commercially available reagents are compared. The international sensitivity index (ISI) describes the responsiveness of each thromboplastin reagent to reductions in the vitamin K–dependent clotting factors compared with a sensitive standard, which is assigned an ISI of 1.0. Commercial thromboplastins derived from animal sources are less sensitive than the reference standard and commonly have ISI values of 1.2 to 2.8.[13] Using the ISI, we can convert PT to an INR with this formula, INR=(patient PT/mean normal PT)^{ISI}. Although the INR has helped to standardize anticoagulant monitoring, problems persist. The precision of INR determination varies, depending on reagent-coagulometer combinations. Unreliable reporting of the ISI by thromboplastin manufacturers also complicates INR determination.[14] Finally, with new batches of thromboplastin reagent, each laboratory must establish a mean normal PT using blood from at least 20 healthy volunteers.[14]

aPTT

The aPTT is performed by first adding a surface activator (eg, kaolin, celite, ellagic acid, or silica) and diluted phospholipid (eg, cephalin) to citrated plasma (Figure 2B). The phospholipid in this assay is called partial thromboplastin because tissue factor is absent. After incubation to allow optimal activation of contact factors (factor XII,

TABLE 1. Causes of Clot-Based Assay Prolongation[10,55]

Scenario	aPTT	INR	TCT
Factor deficiency	Prolonged	Normal	Normal
HMWK			
Prekallikrein			
Factor XII			
Factor XI			
Factor IX			
Factor VIII			
Factor deficiency	Prolonged	Prolonged	Normal
Factor X			
Factor V			
Prothrombin			
Factor deficiency			
Factor VII	Normal	Prolonged	Normal
Factor deficiency			
Fibrinogen	Prolonged	Prolonged	Prolonged
Nonspecific inhibitor	May be prolonged (depends on reagent)	Usually normal	Normal
Heparin (therapeutic doses)	Prolonged	Less affected than aPTT, may be normal	Prolonged
LMWH	Normal	Normal	Prolonged
Hirudin, bivalirudin, argatroban	Prolonged	Variably prolonged	Prolonged
Warfarin (therapeutic doses)	Less affected than INR, may be normal	Prolonged	Normal
Vitamin K deficiency	Less affected than INR, may be normal	Prolonged	Normal
Liver dysfunction	Less affected than INR, may be normal	Usually prolonged	Prolonged
DIC	Less affected than INR	Usually prolonged	Usually prolonged

HMWK indicates high-molecular-weight kininogen; DIC, disseminated intravascular coagulation.

factor XI, prekallikrein, and high-molecular-weight kininogen), calcium is then added, and the clotting time is measured.[9]

Although the clotting time varies according to the reagent and coagulometer used, the aPTT typically ranges between 22 and 40 seconds. The aPTT may be prolonged with deficiencies of contact factors; factors IX, VIII, X, or V; prothrombin; or fibrinogen. Specific factor inhibitors, as well as nonspecific inhibitors, may also prolong the aPTT. Fibrin degradation products and anticoagulants (eg, heparin, direct thrombin inhibitors, or warfarin) also prolong the aPTT, although the aPTT is less sensitive to warfarin than is the PT.[15]

Thrombin Clotting Time

The thrombin clotting time (TCT) is performed by adding excess thrombin to plasma (Figure 2C). The TCT is prolonged in patients with low fibrinogen levels or dysfibrinogenemia and in those with elevated fibrin degradation product levels.[9] These abnormalities are commonly seen with disseminated intravascular coagulation. The TCT is also prolonged by heparin and direct thrombin inhibitors.[10]

Activated Clotting Time

The activated clotting time (ACT) (Figure 2D) is a point-of-care whole-blood clotting test used to monitor high-dose heparin therapy or treatment with bivalirudin.[10] The dose of heparin or bivalirudin required in these settings is beyond the range that can be measured with the aPTT.[16] Typically, whole blood is collected into a tube or cartridge containing a coagulation activator (eg, celite, kaolin, or glass particles) and a magnetic stir bar, and the time taken for the blood to clot is then measured.[10] The reference value for the ACT ranges between 70 and 180 seconds. The desirable range for anticoagulation depends on the indication and the test method used. During cardiopulmonary bypass surgery, the desired ACT range with heparin may exceed 400 to 500 seconds.[17] In contrast, in patients undergoing percutaneous coronary interventions, a target ACT of 200 seconds is advocated when heparin is administered in conjunction with a glycoprotein IIb/IIIa antagonist, whereas an ACT between 250 and 350 seconds is targeted in the absence of such adjunctive therapy.[18] The ACT does not correlate well with other coagulation tests.

Ecarin Clotting Time

For the ecarin clotting time (ECT), venom from the *Echis carinatus* snake is used to convert prothrombin to meizothrombin, a prothrombin intermediate that is sensitive to inhibition by direct thrombin inhibitors.[19] The ECT cannot be used to detect states of disturbed coagulation and is useful only for therapeutic drug monitoring. This assay is insensitive to heparin because steric hindrance prevents the heparin-antithrombin complex from inhibiting meizothrombin.[19] Because ecarin also activates the noncarboxylated prothrombin found in plasma of warfarin-treated patients, levels of direct thrombin inhibitors can be assayed even with concomitant warfarin treatment.[19] Although the ECT has been used in preclinical research, the test has yet to be standardized and is not widely available. A chromogenic variant of this assay has also been developed in which ecarin is added to a plasma sample and meizothrombin generation is measured with a chromogenic substrate.[20]

TABLE 2. Variables That Can Influence the Accuracy of Clotting Test Results

Assay	Variable	Explanation
Clot-based and chromogenic assays (eg, aPTT, INR, TCT, and anti–factor Xa assays)	Improper filling of tube	Overfilling or underfilling the tube changes the ratio of blood to anticoagulant. Consequently, overfilling may cause falsely low results, whereas underfilling may cause falsely high results.
	Abnormal hematocrit	Hematocrit >60% can produce falsely elevated results, whereas hematocrit <20% can cause inappropriately low results.
	Clotted specimen	Poor blood collection technique can induce clotting that results in consumption of coagulation factors (especially fibrinogen) and a falsely prolonged result.
	Delay in performing assay	Failure to separate plasma from cells and the subsequent neutralization of heparin by platelet factor 4 released from platelets may result in falsely low values in heparinized samples.
	Anticoagulant contamination	If the sample is drawn from an indwelling line used for anticoagulant infusion, it can easily be contaminated, even if the initial volume drawn is discarded. Samples are best drawn from peripheral veins.
Whole-blood assays (eg, ACT)	Platelet count and function	Decreased platelet count or function may result in a falsely prolonged ACT
	Hemodilution	Decreased concentration of clotting factors may result in falsely prolonged results
	Anticoagulant contamination	If the sample is drawn from an indwelling line used for anticoagulant administration, it can easily be contaminated. Samples are best drawn from peripheral veins.

Chromogenic Assays

Anti–factor Xa assays are used to measure levels of heparin and low-molecular-weight heparin (LMWH). These are chromogenic assays that use a factor Xa substrate onto which a chromophore has been linked (Figure 3). Factor Xa cleaves the chromogenic substrate, releasing a colored compound that can be detected with a spectrophotometer and is directly proportional to the amount of factor Xa present.[7] When a known amount of factor Xa is added to plasma containing heparin (or LMWH), the heparin enhances factor Xa inhibition by antithrombin rendering less factor Xa available to cleave the substrate.[10] By



Figure 2. A, PT. Thromboplastin reagent containing tissue factor (TF) and calcium is added to citrated plasma. Formation of extrinsic tenase results in rapid fibrin formation via extrinsic and common pathways. B, aPTT. Partial thromboplastin reagent consisting of surface activator and dilute phospholipid is added to citrated plasma. After incubation to allow activation of contact factors and generation of factor IXa, calcium is added to induce clotting via intrinsic and common pathways. C, TCT. Thrombin is added to citrated plasma and directly converts fibrinogen to fibrin. D, ACT. In contrast to PT, aPTT, and TCT, which are done in citrated plasma, ACT is performed in whole blood. Clotting is initiated by adding activator of intrinsic pathway such as celite, kaolin, or glass beads. Once thrombin (IIa) is generated, it induces both platelet aggregation and fibrin formation.



Figure 3. Factor Xa heparin assay. Factor Xa is added to plasma containing synthetic factor Xa substrate that has chromophore attached to 1 end. When substrate is cleaved by factor Xa, chromophore undergoes color change, which can be quantified. Extent of color change is directly proportional to enzyme activity. If heparin or LMWH is present in plasma sample, it will promote factor Xa inhibition by antithrombin rendering less factor Xa available to cleave substrate. By comparing result to extent of substrate hydrolysis in samples containing known amounts of heparin, we can calculate heparin concentration in plasma.

correlating this result with a standard curve produced with known amounts of heparin, we can calculate the heparin concentration in the plasma.

Use of Anticoagulant Assays to Monitor Therapy

Anticoagulant drugs in clinical use include warfarin, heparins (unfractionated heparin and LMWH), and direct thrombin inhibitors (bivalirudin, hirudin, and argatroban).

Warfarin

Warfarin is effective for primary and secondary prevention of venous thromboembolism; for prevention of cardioembolic events in patients with atrial fibrillation or prosthetic heart valves; for prevention of stroke, recurrent infarction, or cardiovascular death in patients with acute myocardial infarction; and for the primary prevention of acute myocardial infarction in high-risk men.[21] Warfarin dosage is usually adjusted to attain a desired INR (Table 3). Because of the variability in the anticoagulant response to warfarin,[21] which reflects genetic variations in metabolism and environmental factors such as medications, diet, and concomitant illness,[21] regular coagulation monitoring and dosage adjustment are required to maintain the INR within the therapeutic range.[21]

Heparins

Heparins are indirect anticoagulants that activate antithrombin and promote its capacity to inactivate thrombin and factor Xa.[22,23] To catalyze thrombin inhibition, heparin binds both to antithrombin via a high-affinity pentasaccharide sequence and to thrombin. In contrast, to promote factor Xa inhibition, heparin needs only to bind to antithrombin via its pentasaccharide sequence. Heparin molecules containing <18 saccharide units are too short to bind to both thrombin and antithrombin and therefore cannot catalyze thrombin inhibition. However, these shorter heparin fragments can catalyze factor Xa inhibition, provided that they contain the pentasaccharide sequence.[24] Because almost all of the chains of unfractionated heparin are of sufficient length to bridge antithrombin to thrombin, heparin promotes thrombin and factor Xa inhibition equally well and is assigned a ratio of anti-Xa to anti-IIa of 1.[25]

The anticoagulant response to heparin is unpredictable because of variable nonspecific binding to endothelial cells, monocytes, and plasma proteins.[25] Because of this variable anticoagulant response, coagulation monitoring is routinely performed when heparin is given in greater than prophylactic doses. The aPTT is the test most often used to monitor heparin.[17] Unfortunately, aPTT reagents vary in their responsiveness to heparin, and the aPTT therapeutic range differs, depending on the sensitivity of the reagent and the coagulometer used for the test.[26,27] The aPTT has proved more difficult to standardize than the PT, and the commonly quoted therapeutic range of 1.5 to 2.5 times the control value often leads to systematic administration of subtherapeutic heparin doses.[17] Consequently, it is recommended that the therapeutic aPTT for heparin correspond to that which results in a heparin concentration of 0.35 to 0.7 anti–factor Xa heparin units per 1 mL.[17] However, evidence supporting the concept of an aPTT therapeutic range that predicts efficacy and safety (with respect to bleeding) is somewhat tenuous.[28]

Approximately 25% of patients require doses of heparin of >35 000 U/d to obtain a therapeutic aPTT and are called heparin resistant.[29] Most of these patients have therapeutic heparin levels when measured with the anti-Xa assay, and the discrepancy between the 2 tests is the result of high concentrations of procoagulants such as fibrino-

TABLE 3. Optimal Therapeutic Range for the INR in Various Indications

Indication for Warfarin Therapy	Therapeutic INR Range
Venous thromboembolism (prevention and treatment)	2.0–3.0
Atrial fibrillation	2.0–3.0
Valvular heart disease	2.0–3.0
Heart valves	
Tissue valves*	2.0–3.0
Mechanical valves	
Bileaflet aortic position	2.0–3.0
High-risk valve	2.5–3.5
Acute myocardial infarction	
Prevention of embolism	2.0–3.0
Prevention of reinfarction	3.5–4.5

*When required.

gen and factor VIII, which shorten the aPTT.[30] Heparin therapy in these patients can be managed safely with heparin levels.[30] Less often, patients with a subtherapeutic aPTT also have a subtherapeutic heparin level despite large doses of heparin. This scenario usually reflects a combination of increased levels of heparin-binding proteins and increased heparin clearance.[31] Rarely, this form of heparin resistance is caused by low levels of antithrombin.

Although the aPTT response is linear with heparin levels within the therapeutic range, the aPTT becomes immeasurable with higher heparin doses.[10] Thus, a less sensitive test of global anticoagulation such as the ACT is used to monitor the level of anticoagulation in patients undergoing percutaneous coronary interventions or aortocoronary bypass surgery.[16] Although several retrospective studies defined an inverse relationship between the likelihood of a thrombotic event and the ACT after heparin administration for percutaneous coronary intervention (PCI),[32,33] more recent data suggest that ischemic end points do not increase with decreasing ACT values, provided that the ACT is ≥200 seconds.[34]

LMWH is derived from unfractionated heparin by chemical or enzymatic depolymerization. With a mean molecular weight about one third that of unfractionated heparin, only 25% to 50% of LMWH molecules contain ≥18 saccharides.[17] Consequently, these agents have ratios of anti-Xa to anti-IIa that range from 2:1 to 4:1.

LMWH has gradually replaced heparin for most indications. LMWH is typically administered in fixed doses when given for prophylactic purposes or in weight-adjusted doses when given for treatment. LMWH has advantages over heparin that enable once- or twice-daily subcutaneous administration without coagulation monitoring (Table 4). Exceptions include patients with renal dysfunction (shorter LMWH chains are cleared via the kidneys), those at extremes of weight, infants, and perhaps pregnant women who are receiving full treatment doses.[17,35–37] LMWH has little effect on the aPTT. Consequently, when monitoring is required, anti-Xa levels are measured with an LMWH standard.[29,38]

TABLE 4. Advantages of LMWH Over Heparin and Their Consequences

Advantage	Mechanism
Better bioavailability after subcutaneous injection	Can be given subcutaneously for prevention or treatment of thrombosis
Longer half-life	Can be given once or twice daily
More predictable anticoagulant response	Routine coagulation monitoring is not necessary
Less platelet activation and binding to platelet factor 4	Reduced risk of heparin-induced thrombocytopenia

Pitfalls in the monitoring of LMWH by anti–factor Xa levels include poor comparability between commercially available anti-Xa chromogenic assays,[35] differences in ratios of anti-Xa to anti-IIa among the various LMWH preparations,[35] and the importance of timing of blood sampling in relation to dosing.[35] In general, it is recommended that blood samples for LMWH monitoring be obtained 4 hours after a subcutaneous injection. Although the relationship between anti-Xa levels and clinical outcomes is unclear,[35,39] typically recommended therapeutic anti-Xa levels for twice-daily LMWH therapy range from 0.5 to 1.0 U/mL and for once-daily treatment between 1.0 and 2.0 U/mL.[10]

Although the aPTT may be prolonged with high doses of LMWH, this assay is not used for monitoring. Because LMWH has less effect on the ACT than heparin,[40–42] empiric LMWH dosing algorithms have been developed in the PCI setting.[18,43]

Direct Thrombin Inhibitors

Direct thrombin inhibitors bind directly to thrombin and block the interaction of thrombin with its substrates. Three parenteral direct thrombin inhibitors have been licensed for limited indications in North America. Hirudin and argatroban are approved for treatment of patients with heparin-induced thrombocytopenia, whereas bivalirudin is licensed as an alternative to heparin in patients undergoing PCI.

Hirudin and argatroban require routine monitoring. The TCT is too sensitive to small amounts of hirudin and argatroban to be used for this purpose.[10] Although the ACT has been used to monitor the higher doses of direct thrombin inhibitors required in interventional settings, it does not provide an optimal linear response at high concentrations.[7] The aPTT is recommended for therapeutic monitoring; however, each direct thrombin inhibitor has its own dose response, and the sensitivity of the test to drug levels varies between aPTT reagents. When hirudin therapy is monitored with the aPTT, the dose is adjusted to maintain an aPTT that is 1.5 to 2.5 times the control, whereas for argatran, the target aPTT is 1.5 to 3 times control (but not to exceed 100 seconds). The aPTT appears less useful in patients requiring higher doses of direct thrombin inhibitor in cardiopulmonary bypass procedures because this test becomes less responsive at increasing drug concentrations.[44] The ECT appears to be useful for both low and high concentrations of direct thrombin inhibitors and is less affected by interfering substances than the aPTT.[7] However, as stated above, it is not routinely available.

The responsiveness of the INR to different drug concentrations differs with assay reagent and with the type of direct thrombin inhibitor.[7] Although all direct thrombin inhibitors prolong the INR, argatroban has the greatest effect on this test. This feature complicates the transitioning of patients with heparin-induced thrombocytopenia from argatroban to vita-

min K antagonists.[45] In general, with doses of argatroban up to 2 $\mu g \cdot kg^{-1} \cdot min^{-1}$, argatroban can be discontinued when the INR is >4.[46] After argatraban is discontinued, the INR is repeated in 4 to 6 hours. If the repeated INR is below the therapeutic range, the argatraban infusion is resumed, and the procedure is repeated daily until the desired therapeutic INR on warfarin alone is reached. For doses >2 $\mu g \cdot kg^{-1} \cdot min^{-1}$, the relationship between the INR on warfarin and argatroban is less predictable. It is recommended that the dose of argatroban be temporarily reduced to 2 $\mu g \cdot kg^{-1} \cdot min^{-1}$ and the INR checked in 4 to 6 hours. The procedure outlined previously should then be followed.

Point-of-Care Monitoring

Most coagulation assays are performed in centralized laboratories using blood collected from indwelling lines or via venipuncture. This approach introduces problems with respect to turnaround time, venous access requirements, and difficulties associated with sample transport and processing. To circumvent these problems, several point-of-care coagulation tests have been introduced. Of these, the ACT remains the most commonly used, reflecting, at least in part, the lack of rapid, readily available, inexpensive alternatives. Point-of-care INR monitoring is both feasible and practical[47] and is used by many specialized coagulation clinics to streamline care. Although there are concerns about discrepancies between INR results obtained by near-patient testing and those measured in hospital laboratories, several investigators have reported that self-management with point-of-care INR devices is safe for selected patients and results in the same quality of care provided by specialized anticoagulation clinics.[48–51] Although point-of-care aPTT results appear to be clinically reliable and reproducible, there is less experience with these techniques.[52] The varying responsiveness of aPTT reagents and the need for calibration with heparin levels to establish an appropriate aPTT range limit the utility of these tests. There is a point-of-care device that can be used to monitor anti-Xa levels. This clot-based test detects LMWH levels above or below 1.0 U/mL. Warfarin, liver disease, and coagulation factor deficiencies can produce falsely high readings with this system.[7] A point-of-care test based on the ECT also has been developed for monitoring direct thrombin inhibitors, but the test has yet to be fully validated.[53,54]

Point-of-care tests are more expensive than centralized assays.[52] Therefore, cost-effectiveness analyses are needed to justify their widespread use.

Review of Cases

Case 1

The attending physician was not surprised that Mr F's aPTT was unaffected by LMWH. The physician debated performing an anti-Xa level but, on the basis of the results of the SYNERGY trial, which used a fixed-dosing strategy, decided that the result would not change management.[43] Mr F proceeded to catheterization as scheduled. Because Mr F's last dose of enoxaparin was given <8 hours before balloon inflation, no additional enoxaparin was given during the procedure. Mr F's sheath was removed 8 hours after his last enoxaparin dose, and there were no complications.

Case 2

Mrs G's physician drew blood for an anti-Xa level at the same time as her next aPTT. Although Mrs G's aPTT remained subtherapeutic at 50 seconds, her anti-Xa level was 0.40 U/mL. Because the heparin level was well within the therapeutic range, heparin was dosed according to daily anti-Xa levels. Warfarin therapy was continued. By the seventh day of heparin therapy, Mrs G's INR was >2.0 for 2 consecutive days, and the heparin was discontinued. Mrs G was discharged home on warfarin, and a repeated INR was ordered 3 days later.[55]

References

1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. *N Engl J Med*. 1992;326:242–250.
2. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. *Arterioscler Thromb Vasc Biol*. 2003;23:17–25.
3. Kumar R, Beguin S, Hemker HC. The effect of fibrin clots and clot-bound thrombin on the development of platelet procoagulant activity. *Thromb Haemost*. 1995;74:962–968.
4. Kumar R, Beguin S, Hemker HC. The influence of fibrinogen and fibrin on thrombin generation: evidence for feedback activation of the clotting system by clot-bound thrombin. *Thromb Haemost*. 1994;72:713–721.
5. Gailani D, Broze GJ Jr. Factor XI activation by thrombin and factor XIa. *Semin Thromb Hemost*. 1993;19:396–404.
6. Furie B, Furie BC. Molecular and cellular biology of blood coagulation. *N Engl J Med*. 1992;326:800–806.
7. Walenga JM, Hoppensteadt DA. Monitoring the new antithrombotic drugs. *Semin Thromb Hemost*. 2004;30:683–695.
8. Suchman AL, Griner PF. Diagnostic uses of the activated partial thromboplastin time and prothrombin time. *Ann Intern Med*. 1986; 104:810–816.
9. White GC II, Marder VJ, Colman RW, Hirsh J, Salzman EW. Approach to the bleeding patient. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. *Hemostasis and Thrombosis: Basic Principles and Clinical Practice*. 3rd ed. Philadelphia, Pa: JB Lippincott Co; 1994:1134–1147.
10. Van Cott EM, Laposata M. Coagulation. In: Jacobs DS, Oxley DK, DeMott WR, eds. *The Laboratory Test Handbook*. 5th ed. Cleveland, Ohio: Lexi-Comp; 2001:327–358.
11. Kirkwood TB. Calibration of reference thromboplastins and standardization of the prothrombin time ratio. *Thromb Haemost*. 1983;49:238–244.
12. Zucker S, Cathey MH, Sox PJ, Hall EC. Standardization of laboratory tests for controlling anticoagulant therapy. *Am J Clin Pathol*. 1970;53:348–354.
13. Bussey HI, Force RW, Bianco TM, Leonard AD. Reliance on prothrombin time ratios causes significant errors in anticoagulation therapy. *Arch Intern Med*. 1992;152:278–282.
14. Hirsh J. Oral anticoagulant drugs. *N Engl J Med*. 1991;324:1865–1875.
15. Hauser VM, Rozek SL. Effect of warfarin on the activated partial thromboplastin time. *Drug Intell Clin Pharm*. 1986;2:964–966.
16. Dougherty KG, Gaos CM, Bush HS, Leachman DR, Ferguson JJ. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. *Cathet Cardiovasc Diagn*. 1992;26:260–263.
17. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and

Thrombolytic Therapy. *Chest*. 2004;126:188S–203S.
18. Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JI. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004;126:576S–599S.
19. Nowak G. The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. *Pathophysiol Haemost Thromb*. 2003/04;33:173–183.
20. Lange U, Nowak G, Bucha E. Ecarin chromogenic assay: a new method for quantitative determination of direct thrombin inhibitors like hirudin. *Pathophysiol Haemost Thromb*. 2003/4;33:184–191.
21. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists. *Chest*. 2004;126:204S–233S.
22. Rosenberg RD, Bauer KA. The heparin-antithrombin system: a natural anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. *Hemostasis and Thrombosis: Basic Principles and Clinical Practice*. 3rd ed. Philadelphia, Pa: JB Lippincott Co; 1994:837–860.
23. Jesty J, Lorenz A, Rodriguez J, Wun TC. Initiation of the tissue factor pathway of coagulation in the presence of heparin: control by antithrombin III and tissue factor pathway inhibitor. *Blood*. 1996;87:2301–2317.
24. Casu B, Oreste P, Torri G, Zoppetti G, Choay J, Lormeau JC, Petitou M, Sinay P. The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. *Biochem J*. 1981;97:599–609.
25. Hirsh J. Heparin. *N Engl J Med*. 1991;324:1565–1574.
26. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. *Ann Intern Med*. 1993;119:104–109.
27. Bates SM, Weitz JI, Johnston M, Hirsh J, Ginsberg JS. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. *Arch Intern Med*. 2001;161:385–391.
28. Hirsh J, Bates S. The multiple faces of the partial thromboplastin time APTT. *J Thromb Haemost*. 2004;2:2254–2256.
29. Hirsh J, Salzman EW, Marder VJ. Treatment of venous thromboembolism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. *Hemostasis and Thrombosis: Basic Principles and Clinical Practice*. 3rd ed. Philadelphia, Pa: JB Lippincott Co; 1994:1346–1366.
30. Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz JI, Anderson D, Johnston M. A randomized trial comparing the activated partial thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. *Arch Intern Med*. 1994;154:49–56.
31. Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. *Thromb Haemost*. 1992;67:639–643.
32. Topol EJ, Bonan R, Jewitt D, Sigwart U, Kakkar VV, Rothman M, de Bono D, Ferguson J, Willerson JT, Strony J. Use of a direct antithrombin, hirulog, in place of heparin during coronary angioplasty. *Circulation*. 1993;87:1622–1629.
33. Narins CR, Hillegass WB, Nelson CL, Tcheng JE, Harrington RA, Phillips HR, Stack RS, Califf RM. Relation between activated clotting time during angioplasty and abrupt closure. *Circulation*. 1996;93:667–671.
34. Brener SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE, Topol EJ. Relationship between activated clotting time and ischemic or hemorrhage complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. *Circulation*. 2004;110:994–998.
35. Bounameaux H, de Moerloose P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. *J Thromb Haemost*. 2004;2:551–554.
36. Sutor AH, Masticate P, Leaker M, Andrew M. Heparin therapy in pediatric patients. *Semin Thromb Hemost*. 1997;23:303–319.
37. Massicotte P, Julian JA, Gent M, Shields K, Marzinotto V, Szechtman B, Andrew M, for the REVIVE Study Group. An open-label randomized trial of low-molecular-weight heparin compared to heparin and Coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial. *Thromb Res*. 2003;109:85–92.
38. Kitchen S, Iamietro R, Wooley AM, Preston FE. Anti-factor Xa monitoring during treatment of LMWH or danaparoid: inter-assay variability. *Thromb Haemost*. 1999;82:1289–1293.
39. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, Kher A, Aiach M, Fiessinger JN. Adjusted versus fixed-doses of the low-molecular-weight heparin Fragmin in the treatment of deep vein thrombosis. *Thromb Haemost*. 1994;71:698–702.
40. Greiber S, Weber U, Galle J, Bramer P, Schollmeyer P. Activated clotting time is not a sensitive parameter to monitor anticoagulation with low molecular-weight heparin in hemodialysis. *Nephron*. 1997;76:15–19.
41. Rabah MM, Premmereur J, Graham M, Fareed J, Hoppensteadt DA, Grines LL, Grines CL. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. *Am J Cardiol*. 1999;84:1391–1395.
42. Linkins L-A, Julian JA, Rischke J, Hirsh J, Weitz JI. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. *Thromb Res*. 2002;107:241–244.
43. SYNERGY Trial Investigators. Enoxaparin vs. unfractionated heparin in high-risk patients with non-ST segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY Randomized Trial. *JAMA*. 2004;292:45–54.
44. Nowak G. Clinical monitoring of hirudin and direct thrombin inhibitors. *Semin Thromb Haemost*. 2001;27:537–541.
45. Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. *Thromb Haemost*. 2001;85:435–440.
46. Harder S, Graff J, Klinkhardt U, von Hentig N, Walenga JM, Watanabe H Osakabe M, Breddin HK. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on prothrombin time, activated partial thromboplastin time, and ecarin clotting time. *Thromb Haemost*. 2004;91:1137–1145.
47. McCurdy SA, White RH. Accuracy and precision of a portable anticoagulation monitor in a clinical setting. *Arch Intern Med*. 1992;152:589–592.
48. Cromheecke ME, Levi M, Colly LP, de Mol BJ, Prins MH, Hutten BA, Mak R, Keyzers KC, Buller HR. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomized cross-over comparison. *Lancet*. 2000;356:97–102.
49. Taborski U, Muller-Berghaus G. State of the art patient self-management for control of oral anticoagulation. *Semin Thromb Hemost*. 1999;25:43–47.
50. Gadisseur AP, Breukink-Engbers WG, van der Meer FJ, van den Besselaar AM, Sturk A, Rosendaal FR. Comparison of the quality of oral anticoagulation therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial. *Arch Intern Med*. 2003;163:2639–2646.
51. Menedez-Jandula B, Souto JC, Oliver A, Montserrat I, Quntana M, Gich I, Bonfill X, Fontcuberta J. Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial. *Ann Intern Med*. 2005;142:1–10.
52. Zimmerman CR. The role of point-of-care anticoagulation monitoring in arterial and venous thromboembolic disorders. *J Thromb Thrombolysis*. 2000;9:187–198.
53. Cho L, Kottke-Marchant K, Lincoff AM, Roffi M, Reginelli JP, Kaldus T, Moliterno DJ. Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations. *Am J Cardiol*. 2003;91:1110–1113.
54. Casserly IP, Kereiakes DJ, Gray WA, Gibson PH, Lauer MA, Reginelli JP, Moliterno DJ. Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration. *Thromb Res*. 2004;113:115–121.
55. Hirsh J, Brain EA, eds. Laboratory diagnosis of bleeding disorders. In: *Hemostasis & Thrombosis: A Conceptual Approach*. 2nd ed. New York, NY: Churchill Livingston; 1983:39–46.